Scholarlink

Background <p>Access to healthcare and socioeconomic deprivation are intricately linked. No studies have been led to measure the effect of healthcare accessibility on mortality in patients with MS so far. The objective was to examine the influence of travel time to the expert MS centre and of the accessibility to primary healthcare services on excess mortality in MS.</p> Methods <p>A retrospective observational cohort study recruited patients from 18 French MS expert centres, with an onset of MS between 1960 and 2015 and a follow-up of up to 30&#xa0;years. Primary health facility accessibility was measured by the Spatial aCcessibility multiscAlar index. Specialist care accessibility was measured by road travel time to the expert MS centre. Excess death rates (EDR) and excess hazard ratios were studied using additive excess hazard models with multidimensional penalised splines.</p> Results <p>The study included 33,697 patients. Patients with relapsing-onset MS (R-MS) with a travel time of 40&#xa0;min had the lowest EDR (Men: 1.2 deaths per 100 person-years (95%CI [0.8;1.8]), women: 0.8 deaths per 100 person-years 95%CI[0.6;1.2]), lower than patients who lived further from the centre. No effect of primary care access was found for patients with R-MS, and no effect of accessibility to primary or specialised care was found for patients with primary progressive MS.</p> Conclusion <p>This study reveals the impact of travel time to neurologists on excess mortality in patients with R-MS in France. This distance bias association highlights the importance of preventing a potential selection of patients followed in MS expert centres.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Influence of geographical accessibility to specialist and primary care givers on excess mortality of multiple sclerosis patients in France

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年10月27日

查看全文
  • Sarah Wilson,
  • Emmanuelle Leray,
  • Floriane Calocer,
  • Fabien Rollot,
  • Mathieu Fauvernier,
  • Laurent Remontet,
  • Ludivine Launay,
  • Sandra Vukusic,
  • Emmanuelle Le Page,
  • Marc Debouverie,
  • Jonathan Ciron,
  • Aurélie Ruet,
  • Jérôme De Seze,
  • Hélène Zephir,
  • Thibault Moreau,
  • David-Axel Laplaud,
  • Christine Lebrun-Frenay,
  • Pierre Clavelou,
  • Pierre Labauge,
  • Eric Berger,
  • Jean Pelletier,
  • Olivier Heinzlef,
  • Eric Thouvenot,
  • Jean Philippe Camdessanché,
  • Charlotte Arnaud,
  • Nathalie Derache,
  • Pierre Branger,
  • Lydia Guittet,
  • Gilles Defer,
  • Olivier Dejardin

摘要

Background

Access to healthcare and socioeconomic deprivation are intricately linked. No studies have been led to measure the effect of healthcare accessibility on mortality in patients with MS so far. The objective was to examine the influence of travel time to the expert MS centre and of the accessibility to primary healthcare services on excess mortality in MS.

Methods

A retrospective observational cohort study recruited patients from 18 French MS expert centres, with an onset of MS between 1960 and 2015 and a follow-up of up to 30 years. Primary health facility accessibility was measured by the Spatial aCcessibility multiscAlar index. Specialist care accessibility was measured by road travel time to the expert MS centre. Excess death rates (EDR) and excess hazard ratios were studied using additive excess hazard models with multidimensional penalised splines.

Results

The study included 33,697 patients. Patients with relapsing-onset MS (R-MS) with a travel time of 40 min had the lowest EDR (Men: 1.2 deaths per 100 person-years (95%CI [0.8;1.8]), women: 0.8 deaths per 100 person-years 95%CI[0.6;1.2]), lower than patients who lived further from the centre. No effect of primary care access was found for patients with R-MS, and no effect of accessibility to primary or specialised care was found for patients with primary progressive MS.

Conclusion

This study reveals the impact of travel time to neurologists on excess mortality in patients with R-MS in France. This distance bias association highlights the importance of preventing a potential selection of patients followed in MS expert centres.